推薦產(chǎn)品
2-hydroxy-2-(pyrrolidin-2-yl)aceticacid 5-hydroxy-3,3-dimethyldihydrofuran-2(3H)-one methyl3-oxo-4-m-tolylbutanoate ethyl3-oxo-4-o-tolylbutanoate methyl2,4-dioxopentanoate 1H-pyrazolo[3,4-b]pyridine-3-carboxylicacid 5-(2,2,2-trifluoroethoxy)picolinicacid 2,3-dihydroxyterephthalicacid 4-(tert-butoxycarbonyl)morpholine-2-carboxylicacid 2-(4-fluorobenzyloxy)aceticacid 2-(2-fluorocyclohexyloxy)aceticacid 2-(tetrahydro-2H-pyran-4-yloxy)aceticacid 2-(pyridin-4-ylmethoxy)aceticacid 2-(cyclopentyloxy)aceticacid 2-(pyrazin-2-ylmethoxy)aceticacid 2-((4-(trifluoromethyl)pyridin-3-yl)methoxy)aceticacid 2-(pyridazin-3-yloxy)aceticacid 2-(pyridin-2-ylamino)aceticacid 2-(1H-pyrrolo[3,2-b]pyridin-3-yl)aceticacid 2-(1H-pyrrolo[2,3-c]pyridin-3-yl)aceticacid 2-(2-methyl-1H-imidazol-1-yl)aceticacid 2-(1H-indol-3-yl)propanoicacid 2-(1H-indol-1-yl)aceticacid 2-(1H-1,2,3-triazol-1-yl)aceticacid 2-(1H-benzo[d][1,2,3]triazol-1-yl)aceticacid ethyl2-bromo-2-phenylacetate ethyl2-bromo-2-(2-bromophenyl)acetate 1-(tert-butoxycarbonyl)azetidine-3-carboxylicacid 1-(benzyloxycarbonyl)pyrrolidine-3-carboxylicacid 1-tert-butyl3-methylazetidine-1,3-dicarboxylate 2-methylpyrido[2,3-b]pyrazin-3(4H)-one isothiazol-4-aminehydrochloride tert-butyl2-oxa-7-azaspiro[3.5]nonane-7-carboxylate 2-oxa-7-azaspiro[3.5]nonane 4-hydrazinylpyridin-2(1H)-one (7H-pyrrolo[2,3-d]pyrimidin-4-yl)methanaminehydrochloride 1-cyclopropylpiperazine 7-oxa-2-azaspiro[3.5]nonanehydrochloride 4,4-difluorocyclohexanaminehydrochloride 4-(1,3,4-oxadiazol-2-yl)aniline 4-(1,2,4-oxadiazol-3-yl)aniline 3,4-dihydro-2H-benzo[b][1,4]oxazine 3-(1-methyl-1H-pyrazol-4-yl)aniline piperazin-2-one methylpyrrolidine-3-carboxylate 2-(8-fluoronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 6-(dimethylamino)-4-methylpyridin-3-ylboronicacid 3-bromo-7-chloro-5-methyl-1H-pyrazolo[4,3-b]pyridine 7-chloro-5-methyl-1H-pyrazolo[4,3-b]pyridine 5-bromo-3,3-dimethylindolin-2-one 市場(chǎng)行情 4月16日華東BDO市場(chǎng)商談弱勢(shì)，華東地區(qū)主力炔醛法生產(chǎn)企業(yè)維持長(zhǎng)約合同，市場(chǎng)貿(mào)易商隨行就市，對(duì)后期并不看好，下游剛需交投有限。
